Second source of growth quietly turning on: management is adding a new way to grow that does not require winning new dem
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司近期获得了一种不依赖说服新客户购买的新增长方式,即增长来自公司内部已有的东西,并且管理层描述这已经开始在当前时期产生效果。 在电话会议中,管理层提到了多个内部增长来源: 1. 关于EYLEA,管理层提到“EYLEA category share was approaching previous levels of approximately 50% of injections”以及“We believe we have substantially recovered from the issue encountered in the fourth quarter.” 这暗示了市场份额的恢复,但这是否是“新方式”? 2. 关于Dupixent,管理层提到“Dupixent is now approved in 5 related Type 2 allergic conditions”以及“we have an opportunity to reach even more patients with potential regulatory approvals in new diseases, geographies and younger populations” 这更多是扩展适应症,属于赢得新需求。 3. 关于aflibercept 8毫克,管理层提到“we are preparing for a potential U.S. launch for aflibercept 8 milligrams in late August” 这是新产品,属于新需求。 4. 关于Libtayo,管理层提到“Libtayo is also emerging as an essential backbone of our oncology pipeline” 以及“we are moving forward with expansion beyond melanoma to include lung cancer” 这也是扩展适应症。 5. 关于成本协同,管理层提到“we are continuing dose expansion in our Phase 1/2 PSMAxCD28 program” 这是研发进展。 但问题核心是:是否有一种增长方式不依赖新客户,而是利用已有资产、客户、能力等,并且已经开始产生效果。在电话会议中,管理层提到了“we have identified a potent broadly neutralizing COVID-19 antibody” 但这是新药,不是内部增长。 更关键的是,管理层提到了“we no longer expect to record any material other operating income or expense in 2023 or beyond” 这是财务调整。 仔细阅读,管理层提到了“we are preparing for a potential U.S. launch for aflibercept 8 milligrams” 这是新产品,但它是基于已有的EYLEA平台,但仍然是新客户。 有没有提到“selling more to customers it already has” ?例如,Dupixent在已有适应症中增加患者?但管理层提到“Dupixent continues to perform well in the highly competitive biologic asthma space with steady market share gains” 这是市场份额增长,但仍然是赢得新患者。 管理层提到“we have an opportunity to reach even more patients with potential regulatory approvals in new diseases” 这是新适应症,新需求。 关于“using capacity, assets, data, approvals, or an installed base it already owns in a new or fuller way” ?管理层提到“we are planning to rapidly move forward with clinical development of our next-generation COVID-19 antibody” 但这是新药。 或许“reducing what it loses” ?管理层提到“We believe we have substantially recovered from the issue encountered in the fourth quarter” 这是恢复,但不算新增长。 整体来看,管理层描述的增长主要来自新适应症、新市场、新产品,这些都是赢得新需求。没有明确提到一种内部增长方式,比如提高价格、增加现有客户的使用量等。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| NMR | Nomura Holdings, Inc. | Q1 2024 | 2023-08-02 | D |
| GS | The Goldman Sachs Group, Inc. | Q2 2023 | 2023-07-19 | C+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| ALGN | Align Technology, Inc. | Q4 2022 | 2023-02-01 | F |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CCRN | Cross Country Healthcare, Inc. | Q1 2022 | 2022-05-04 | B |
| ARCC | Ares Capital Corporation | Q1 2022 | 2022-04-26 | B |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| ZH | Zhihu Inc. | Q3 2021 | 2021-11-22 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| ARKR | Ark Restaurants Corp. | Q1 2016 | 2016-05-13 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
MKTX · Q3 2017 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this dynamic in open trading. Rick notes that “Open trading is increasingly becoming an important distribution channel for dealers and their efforts to increase trading velocity and reduce balance sheet usage,” and that “Our vast network of investors and dealers operating on the open trading platform provide an additive tool of liquidity for dealers to move bonds.” Dealer-initiated open trades hit a new high of 24 % of total volume, and open trading already accounts for 37 % of U.S. high-yield volume, 15 % of high-grade, and 13 % of emerging-market volume. These metrics are presented as current-quarter results (new record participation, 51 % rise in price responses, $56 billion traded, ADV +29 %, transactions +45 %), not as future plans. Management treats this as a meaningful, already-operating growth engine that runs on the company’s existing installed base of liquidity providers and clients rather than on winning new ones. The same logic appears in the micro-lot discussion, where the platform’s existing liquidity is already capturing 23 % share of sub-$250 k trades—greater than all other retail ATS platforms combined—without any new customer acquisition.
ZH · Q3 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing exactly this: the joint-creation feature (launched October) lets text creators authorize video creators to use their existing answers as video scripts and share copyrights, turning 1.8 million pieces of already-authorized content into new videos that drive millions of additional views and engagement. They present this 1.8 million figure and the resulting video metrics (e.g., 4 million-view and 2.59 million-view examples) as real, observable effects already occurring in Q3, not future plans. They tie it directly to higher video consumption penetration (37% of DAUs), creator income, and overall community monetization efficiency, framing it as a meaningful new growth engine that runs on the company’s existing content library and creator base rather than solely on acquiring new users. This is presented as already working and central to sustaining the 115% revenue growth and 110% paid-member growth. The answer is therefore YES.
CRS · Q4 2021 → YESThe question is: Does management describe that the company has recently GAINED A NEW WAY TO GROW THAT DOES NOT DEPEND ON PERSUADING NEW CUSTOMERS TO BUY — something already inside its own walls, and i...YES The transcript shows management describing the hot strip mill commissioning and Athens facility as already enabling new revenue streams from existing soft magnetics and aerospace capabilities (e.g., producing for FAA-certified motors and sensors), with these outputs explicitly tied to current-period activity rather than future plans. This represents an internal growth lever—leveraging 100% owned assets and approvals already in place—independent of acquiring new customers, and management presents it as actively contributing to the recovery narrative in the current quarter. While broader backlog and bookings reflect market demand, the specific mill and qualification details are framed as a fresh, self-contained growth mechanism now in operation.